We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
JARDIANCE (Boehringer Ingelheim Pty Ltd)
Product name
JARDIANCE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
empagliflozin
Registration type
EOI
Indication
Type 2 diabetes mellitus
Glycaemic control
JARDIANCE is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults and children aged 10 years and above.